Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
13. November 2024 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced SneakPeek is now available over the counter in more than 8,800 retail locations.
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
07. November 2024 16:05 ET
|
Myriad Genetics, Inc.
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives.Third...
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
04. November 2024 08:39 ET
|
Myriad Genetics, Inc.
Myriad Genetics comments on UnitedHealthcare’s updated medical policy for pharmacogenetic testing
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
30. Oktober 2024 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics, Inc. (NASDAQ: MYGN) will hold its third quarter earnings conference call on Thursday, Nov. 7, 2024 at 4:30 pm ET.
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
16. Oktober 2024 09:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced a strategic partnership with jscreen to advance health equity and genetic testing access.
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
15. Oktober 2024 09:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics and Flatiron Health partner to make genetic testing more accessible with EMR integration
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
08. Oktober 2024 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research...
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
03. Oktober 2024 09:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a...
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
01. Oktober 2024 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and...
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
18. September 2024 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will showcase 10 studies highlighting...